In human CRC, mutations in the KRAS gene have a frequency of around 30%-40% and were linked to poor outcomes, whereas mutations of the BRAF gene, a downstream molecule of KRAS, occur in only 5%-10% of patients with sporadic diseases. Here, KRAS is linked to colorectal carcinoma.